Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
Significant number of patients with type 2 diabetes mellitus are obese. It is known that even glucose intolerance, as well as diabetes, can lead to vascular complications. At the same time, weight loss can reduce the risk of type 2 diabetes in obese and pre-diabetic patients. According to available...
Enregistré dans:
Auteurs principaux: | Nina A. Petunina, Milena Е. Telnova |
---|---|
Format: | article |
Langue: | EN RU |
Publié: |
Endocrinology Research Centre
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e01b1b31cbfe4e638bb0fff9a524daf6 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
par: Gagik R. Galstyan, et autres
Publié: (2017) -
The associations of incretin hormone concentration with gestational diabetes mellitus
par: Tatiana V. Saprina, et autres
Publié: (2016) -
The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
par: Marina Vladimirovna Shestakova
Publié: (2010) -
Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection
par: Elena Nikolaevna Trunina, et autres
Publié: (2011) -
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
par: Minara S. Shamkhalova, et autres
Publié: (2020)